Recently, TET2 has been considered as a novel tumor suppressor, and TET2 mutations have been demonstrated to be acquired in 12–24% of myeloid neoplasms, including AML, MDS, CMML and MPN19. This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.